Item 8.01 Other Events.

On April 20, 2021, bluebird bio, Inc. (the "Company") issued a press release announcing business and program updates across its severe genetic disease portfolio including a revised diagnosis of transfusion-dependent anemia for a case that was initially reported as myelodysplastic syndrome (MDS) in the HGB-206 study of LentiGlobin for sickle cell disease (bb1111), removal of Zynteglo (betibeglogene autotemcel, beti-cel) for ?-thalassemia from the German market due to the outcome of reimbursement negotiations in Germany, and a reduction in workforce intended to enable the Company to advance its late-stage gene therapy programs.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
    Exhibit
      No.                                             Description
     99.1               Press release issued by bluebird bio, Inc. on     April 20    , 2021.
      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses